Evidence map›Paper›PMID 42614301›Full record

ArticleFrontiers in oncology2026

Diagnostic delays, treatment timeliness, and patient experiences in triple-negative breast cancer: a mixed-methods study.

Marcela Mazo Canola, Rebekkah Schear, Laura T Housman, Kandis V Backus, Cosmina Hogea

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marcela Mazo CanolaDivision of Hematology-Oncology, University of Texas Health San Antonio, San Antonio, TX, United States.
Rebekkah SchearPolaris Global Health Solutions, Austin, TX, United States.
Laura T HousmanAvalere Health, Washington, DC, United States.
Kandis V BackusGilead Sciences, Inc., Foster City, CA, United States.
Cosmina HogeaGilead Sciences, Inc., Foster City, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that disproportionately affects younger patients, and Black and Hispanic/Latina patients. Timely diagnosis and treatment initiation are critical for optimal outcomes, yet variation in care delivery and delays in treatment initiation persist. While administrative data have documented differences in treatment timeliness, less is known about how patients experience the early TNBC care pathway and how these experiences relate to observed healthcare utilization patterns. Methods: We conducted a convergent parallel mixed-methods study integrating qualitative interviews with patients diagnosed with TNBC and a retrospective analysis of administrative claims data. Semi-structured interviews were conducted with 42 patients in the United States, intentionally oversampling Black, Hispanic/Latina, and younger patients. Quantitative analyses examined screening, diagnostic utilization, time to treatment initiation, and post-treatment care utilization among 6,345 commercially insured patients and patients with Medicaid managed care (MMC). Qualitative and quantitative findings were analyzed independently and then integrated to identify areas of convergence, divergence, and expansion. Results: Quantitative analyses identified observed differences in adjusted time to neoadjuvant treatment initiation among Black and Hispanic/Latina patients enrolled in MMC, with adjusted mean times increasing from 44.2 days (95% CI: 40.7-48.0) among White patients to 63.2 days (95% CI: 58.1-68.8) among Hispanic/Latina patients and 82.1 days (95% CI: 75.3-89.4) among Black patients. Qualitative findings provided context for these observed patterns, with participants describing symptom dismissal, difficulties translating complex clinical information into meaningful understanding, insurance-related barriers, and logistical challenges that may affect escalation and treatment readiness. Divergences highlighted limitations of claims-based measures, including their inability to capture emotional distress, uncertainty, feeling unseen within care interactions, fragmented care experiences, and inadequate preparation for treatment side effects. Conclusion: By integrating patient experiences with claims-based analyses, this study provides hypothesis-generating insights into early TNBC care pathways and identifies potential inflection points where health system interventions, particularly patient navigation and tailored education, may support more equitable, coordinated, and patient-centered care, across the TNBC care continuum.

Indexed as

cancer care pathwayscare coordinationmixed-methodspatient experiencepatient navigationpatient outcomestime to treatmenttriple-negative breast cancer

Identifiers

PMID42614301
PMCPMC13481297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.